Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
Authors:
Open Access
- 7 September 2022
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-12
Abstract
Background: Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic animal model and to determine the molecular and cellular mechanisms underlying its function. Methods: A total of 30 male New Zealand white rabbits were randomized into control, diabetes, or diabetes+dapagliflozin groups (n = 10/per each group). Diabetes was induced by intravenous alloxan. Cardiac function was evaluated using echocardiography. Myocardial samples were obtained for histologic and molecular evaluation. For cellular evaluation, fibrosis-induced cardiomyoblast (H9C2) cells were obtained, and transfection was performed for mechanism analysis (serum and glucocorticoid-regulated kinase 1 (SGK1) signaling analysis). Results: The diabetes+dapagliflozin group showed attenuation of diastolic dysfunction compared with the diabetes group. Dapagliflozin inhibited myocardial fibrosis via inhibition of SGK1 and epithelial sodium channel (ENaC) protein, which was observed both in myocardial tissue and H9C2 cells. In addition, dapagliflozin showed an anti-inflammatory effect and ameliorated mitochondrial disruption. Inhibition of SGK1 expression by siRNA decreased and ENaC and Na+/H+ exchanger isoform 1 (NHE1) expression was confirmed as significantly reduced as siSGK1 in the diabetes+dapagliflozin group. Conclusions: Dapagliflozin attenuated left ventricular diastolic dysfunction and cardiac fibrosis via regulation of SGK1 signaling. Dapagliflozin also reduced macrophages and inflammatory proteins and ameliorated mitochondrial disruption.Keywords
This publication has 39 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in HumansDiabetes, 2013
- Sgk1-Dependent Stimulation of Cardiac Na+/H+Exchanger Nhe1 by DexamethasoneCellular Physiology and Biochemistry, 2013
- Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular RemodelingCirculation, 2012
- Regulation of ion channels by the serum‐ and glucocorticoid‐inducible kinase SGK1The FASEB Journal, 2012
- Impact of Progression of Diastolic Dysfunction on Mortality in Patients With Normal Ejection FractionCirculation, 2012
- Progression of Left Ventricular Diastolic Dysfunction and Risk of Heart FailureJAMA, 2011
- Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatmentEuropean Heart Journal, 2010
- Serum and Glucocorticoid-Responsive Kinase-1 Regulates Cardiomyocyte Survival and Hypertrophic ResponseCirculation, 2005